Lai Wang Sells Shares of BeOne Medicines AG
Lai Wang, President of Global R&D at BeOne Medicines, sold 1,068 shares valued at $295,558.
Key Points
- Lai Wang, President of Global R&D at BeOne Medicines, sold 1,068 shares at $276.74 each on June 23.
- Shares of BeOne Medicines (ONC) traded at $277.12 on Friday, with a market cap of $28.2 billion and a P/E ratio of 61.35.
- RBC Capital and others maintain 'buy' ratings with targets up to $436, while Jefferies downgraded to 'hold' with a $290 target.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Lai Wang, the President and Global Head of R&D at BeOne Medicines AG, sold 1,068 shares of the company on June 23. The shares were sold at an average price of $276.74, resulting in a total transaction value of $295,558. This sale was not part of a pre-planned trading program.
Insider Buying and Selling at BeOne Medicines AG
In addition to Lai Wang's transaction, other insiders at BeOne Medicines have been active. On the same day, CEO John Oyler sold 3,410 shares, and President and COO Xiaobin Wu sold 1,292 shares. These transactions were also not pre-planned.
BeOne Medicines AG Stock Down 24.9%
Shares of NasdaqGS:ONC traded near $277.12 on Friday. BeOne Medicines AG has a market capitalization of approximately $28.2 billion. The company has a P/E ratio of 61.35 and a forward P/E of 27.98, with a beta of 0.493. Over the past 52 weeks, the stock has ranged from a low of $239.25 to a high of $385.22. The 50-day moving average is $295.53, while the 200-day moving average stands at $318.35.
$ONC stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
Several analysts have recently weighed in on BeOne Medicines. RBC Capital maintained its 'buy' rating with a price target of $436 on June 2. Other firms like Leerink Partners and Guggenheim also upheld 'buy' ratings with targets of $367 and $420, respectively. Jefferies, however, downgraded the stock to 'hold' with a $290 target in March.
About BeOne Medicines
BeOne Medicines AG, headquartered in Basel, Switzerland, is a biotechnology company focused on developing treatments for cancer. It operates in the United States, China, and Europe. The company offers several commercial products, including BRUKINSA and TEVIMBRA, and is engaged in multiple clinical trials. BeOne Medicines was formerly known as BeiGene, Ltd. and changed its name in May 2025. It employs around 12,000 people and is led by CEO John V. Oyler.
Bottom Line
Lai Wang's sale of shares in BeOne Medicines AG highlights ongoing insider activity at the company. Investors keep a close eye on such transactions to gauge insider sentiment. While insider trading provides some insight, it's important to remember that these filings are backward-looking and may not reflect current positions or future intentions.
Get BeOne Medicines AG alerts
New 13F filings, insider trades, and analyst moves on $ONC, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.